Imunon (DB:CBO) - Stock Price, News & Analysis

CBO Stock Overview

A clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. More details

CBO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 22% per year for the next 3 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

+ 3 more risks

Imunon, Inc. Competitors

Medigene

XTRA:MDG1

€22.6m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€49.1m

Price History & Performance

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share Price	US$0.66
52 Week High	US$3.70
52 Week Low	US$0.44
Beta	2.13
11 Month Change	-24.57%
3 Month Change	-40.00%
1 Year Change	-6.38%
33 Year Change	-93.02%
5 Year Change	-96.42%
Change since IPO	-99.94%

Recent updates

Shareholder Returns

	CBO	DE Biotechs	DE Market
7D	1.5%	-0.7%	-0.02%
1Y	-6.4%	-17.2%	8.2%

Return vs Industry: CBO exceeded the German Biotechs industry which returned -17.5% over the past year.

Return vs Market: CBO underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is CBO's price volatile compared to industry and market?
CBO volatility
CBO Average Weekly Movement	9.5%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CBO's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: CBO's weekly volatility has decreased from 35% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
CBO fundamental statistics
Market cap	€9.65m
Earnings (TTM)	-€18.68m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Is CBO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CBO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$1.67m
Gross Profit	-US$1.67m
Other Expenses	US$17.78m
Earnings	-US$19.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.34
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CBO perform over the long term?

See historical performance and comparison

CBO Stock Overview

Risk Analysis

Imunon, Inc. Competitors

XTRA:MDG1

€22.6m

XTRA:CNW

€6.5m

XTRA:T5O

€1.4m

DB:VSC

€49.1m

Price History & Performance

Recent News & Updates

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Recent updates

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform